Estimating the clinical and budgetary impact of using angiotensin receptor neprilysin inhibitor as first line therapy in patients with HFrEF

Estimating the clinical and budgetary impact of using angiotensin receptor neprilysin inhibitor as first line therapy in patients with HFrEF

Abstract Aims Recent updates of international treatment guidelines for heart failure with reduced ejection fraction (HFrEF) differ regarding the use of angiotensin receptor neprilysin inhibitor (ARNI) as first‐line treatment. The American Heart Association/American College of Cardiology/Heart Failur...

Full description

Bibliographic Details
Main Authors: Nicklas Bergh, Krister Lindmark, Johannes Lissdaniels, Gustav Lanne, Oskar Käck, Martin R. Cowie
Format: Article
Language:English
Published: Wiley 2024-04-01
Series:ESC Heart Failure
Subjects:
ARNI
ESC vs. ACC
Health economic analysis
Health outcome
HFrEF
Quadruple GDMT
Online Access:https://doi.org/10.1002/ehf2.14551

Internet

https://doi.org/10.1002/ehf2.14551

Similar Items